Guangdong Taienkang Pharmaceutical Co., Ltd.

Equities

301263

CNE1000058X0

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-06-26 pm EDT 5-day change 1st Jan Change
12.48 CNY -2.88% Intraday chart for Guangdong Taienkang Pharmaceutical Co., Ltd. -2.27% -23.58%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Guangdong Taienkang Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023 CI
Guangdong Taienkang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Guangdong Taienkang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Guangdong Taienkang Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 31, 2023. CI
Tranche Update on Guangdong Taienkang Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 31, 2023. CI
Guangdong Taienkang Pharmaceutical Co., Ltd announces an Equity Buyback for CNY 50 million worth of its shares. CI
Guangdong Taienkang Pharmaceutical Co., Ltd authorizes a Buyback Plan. CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Guangdong Taienkang Pharmaceutical Co., Ltd(XSEC:301263) added to S&P Global BMI Index CI
BCY Pharm Co., Ltd. announced that it has received CNY 150 million in funding from Guangdong Taienkang Pharmaceutical Co., Ltd CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
BCY Pharm Co., Ltd. announced that it expects to receive CNY 150 million in funding from Guangdong Taienkang Pharmaceutical Co., Ltd CI
Guangdong Taienkang Pharmaceutical Co., Ltd Approves Cash Dividend on A Shares for the Year 2022, Payable on 29 May 2023 CI
Guangdong Taienkang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for 2022 CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Certain A Shares of Guangdong Taienkang Pharmaceutical Co., Ltd are subject to a Lock-Up Agreement Ending on 30-MAR-2023. CI
Taienkang Pharma to Buy 50% of Local Biomedical Firm For 200 Million Yuan MT
Guangdong Taienkang Pharma to Buy 50% of Local Biomedical Firm For 200 Million Yuan MT
Guangdong Taienkang Pharmaceutical Co., Ltd entered into an investment agreement to acquire BCY Pharm Co., Ltd from Nanjing Baijiahui Biotechnology Development Co., Ltd and others for CNY 200 million. CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Guangdong Taienkang Pharmaceutical Announces A 2021 Final Profit Distribution Payable on 30 May 2022 CI
Guangdong Taienkang Pharmaceutical Co., Ltd Approves Cash Dividend for 2021 CI
Guangdong Taienkang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2021 CI
Chart Guangdong Taienkang Pharmaceutical Co., Ltd.
More charts
Guangdong Taienkang Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development and production of pharmaceutical products. The Company's businesses include agency operation, and sales of pharmaceutical products, medical devices and hygiene materials. The Company's main products include chemical medicines, external medicines, proprietary Chinese medicines, medical devices and hygiene materials. The Company is also engaged in the provision of medical technology services and technology transfer. The Company mainly conducts its businesses in the domestic market.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 301263 Stock
  4. News Guangdong Taienkang Pharmaceutical Co., Ltd.
  5. Guangdong Taienkang Pharma to Buy 50% of Local Biomedical Firm For 200 Million Yuan